| 百度集团-SW | 146.650 | -6.150 | -4.02% | | --- | --- | --- | --- | | 地平线机器人-W | 7.930 | -0.300 | -3.65% | | 商汤-W | 2.380 | -0.090 | -3.64% | | 京东健康 | 60.950 | -2.300 | -3.64% | | 理想汽车-W | 63.600 | -2.350 | -3.56% | | 网易-S | 198.200 | -6.800 | -3.32% | | 金蝶国际 | 12.540 | -0.410 | -3.17% | | 小米集团-W | 34.520 | -0.980 | -2.76% | | 美团-W | 94.650 | -2.550 | -2.62% | 编辑｜钉钉 2月2日，港股低开低走，恒生科技指数午后跌幅扩大至4%；恒指现跌近3%。 科网股集体下跌，华虹半导体跌超12%，比亚迪股份跌超8%，哔哩哔哩跌超5%，快手、阿里巴巴、百 度集团跌逾4%，网易、小米集团、美团均走低。 | 名称 | 现价 | 涨跌 | 涨跌幅 ~ | | --- | --- ...

华宝基金 Al²级八回争夺战打响 从草力崇拜到应用为它 () 热点速递 S 腾讯控股在2月1日上线春节活动,用户上元宝 App分10亿元现金红包,AI应用超级入口的争夺战 再升级。 © 阿里巴巴旗下千问App全面接入淘宝等阿里生态, 开启Al办事新时代。 港股互联网ETF 513770 联接A 017125 联接c 017126 港股Al核心资产 应用爆发!锚定互联网龙头 标的指数重仓港股科技、互联网龙头、腾讯控股+阿里 巴巴-W权重近30%,前十大个股汇聚平台型科技巨 头、大模型及各领域AI应用公司,合计占比超78%,龙 头优势显著。 15.41% 14.49% Tencent 腾讯 € Alibaba 12.35% 3.79% 14.02% 4.10% 美团-W 小米集团-W 商汤-W 快手-W 3.75% 3.31% 3.26% 3.73% 贝壳-W 京东健康 哔哩哔哩-W 金蝶国际 注:权重数据源于中证指数公司,截至2025年12月31日,所示个股均为中证港股通 互联网指数前十大成份股,仅作展示,个股描述不作为任何形式的投资建议,也不代 表管理人旗下任何墓金的持仓信息和交易动向。 弹性突出! 上涨进攻 ...

Investment Rating - The report does not explicitly provide an investment rating for the industry or specific companies involved in the internet-based first consultation pilot in Beijing. Core Insights - The pilot program for internet-based first consultations in Beijing is expected to have landmark significance for nationwide policy expansion, aiming to relieve offline clinical pressure and extend quality medical resources digitally across China [2][6]. - The policy is anticipated to drive online traffic growth and accelerate prescription outflow, particularly in specialties suitable for remote diagnosis such as dermatology, mental health, and nutrition [7][8]. - The integration of "consultation-examination-diagnosis-medication" services is facilitated by this policy, potentially streamlining patient journeys and reducing transportation costs [8]. Summary by Sections Event - On January 31, 2026, the National Health Commission approved a pilot for internet-based first consultations in pediatric specialties in Beijing, running from January to December 2026 [1][5]. Commentary - The pilot aims to address the medical needs of out-of-town patients and relieve non-capital functions in Beijing, with the potential to serve as a reference for similar initiatives nationwide [2][6]. - If the scope of internet-based first consultations expands, it could lead to significant growth in online consultations and related health product sales [7]. - Leading companies like Alibaba Health and JD Health are expected to benefit from the expansion of this policy [8].

Investment Rating - The report maintains an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, while China National Pharmaceutical Group is rated "Neutral" [1]. Core Insights - The Hong Kong healthcare sector experienced a broad-based correction due to capital pressures, with pharmaceutical distribution remaining relatively stable [4][28]. - The Hang Seng Healthcare Index fell by 3.0% this week, underperforming the Hang Seng Index by 5.4 percentage points, but has gained 8.6% year-to-date, outperforming the Hang Seng Index by 1.7 percentage points [14][27]. - The top five gainers in the sector included Leads Biolabs-B (+19.3%), Sihuan Pharmaceutical (+17.9%), and Tigermed (+7.6%), while the bottom five decliners included Medlive Technology (-16.2%) and Laekna-B (-14.1%) [4][29]. Summary by Sections Market Performance - The report indicates that various sub-sectors within the Hong Kong healthcare market experienced declines, with pharmaceutical distribution down by 0.3%, internet healthcare down by 2.1%, and medical devices down by 5.0% [4][28]. Company Highlights - Rongchang Biopharmaceutical announced a revenue forecast of 3.25 billion yuan for 2025, representing an 89% year-on-year increase, and reported a turnaround to profitability [11]. - A collaboration agreement was signed between CSPC Pharmaceutical and AstraZeneca, involving a total payment of $18.5 billion for the licensing of GLP-1 long-acting assets [11]. - AstraZeneca plans to invest $15 billion in China by 2030, focusing on expanding drug manufacturing and R&D capabilities [12]. - Kangzheng Pharmaceutical's lebrikizumab cream has been approved for the treatment of non-segmental vitiligo in patients aged 12 and older [12]. Regulatory Developments - The National Health Commission approved a pilot program for internet-based first consultations in Beijing, which is expected to accelerate prescription outflow and improve access to healthcare services [13].

Core Insights - The report emphasizes the strong potential of the AI industry and high-growth segments such as gaming, recommending continued investment in these areas [2][13][16]. Group 1: Internet Sector - E-commerce: Alibaba is catalyzing AI-related developments, introducing the "Tongyun Ge" concept, which integrates large models, cloud computing, and chips as a key support for its technology strategy [2][16]. - Social Entertainment Media: Bilibili and Tencent are expected to see strong advertising momentum, with Tencent's gaming fundamentals improving and Bilibili preparing to release new games [2][17]. - Internet Healthcare: JD Health and Alibaba Health are leveraging their platform advantages to deepen collaborations with upstream pharmaceutical manufacturers, leading to sustained revenue and profit growth [2][17]. - Short Video: Kuaishou is maintaining a stable core business, with AI technology enhancing user engagement and commercial conversion [2][18]. - Trendy Toys + IP: Pop Mart announced the establishment of its European headquarters in London, aiming to expand its market presence [2][19]. - Long Video: Multiple platforms are releasing quality series, suggesting investment opportunities in iQIYI and Mango TV [2][20]. - Music Streaming: Tencent Music and NetEase Cloud Music show stable performance, although concerns about competition have led to valuation adjustments [2][20]. Group 2: Media Sector - Gaming: The report maintains a positive outlook on the gaming sector, with expectations of continued industry prosperity into 2026. Key recommendations include Tencent, NetEase, and companies with strong product pipelines like Century Huatong and Giant Network [2][21]. - Advertising: Adjustments in the advertising landscape are not expected to impact the operational trends of Focus Media, with increased investment from internet advertisers anticipated [2][22]. - Publishing: Some publishing companies are facing challenges due to educational reforms, but firms with strong fundamentals and high dividend yields are recommended [2][22]. - Film and Television: Attention is drawn to companies with robust project pipelines, such as Huace Film & TV and Mango TV, as well as cinema chains like Wanda Film and Hengdian Film [2][22]. - IP Derivatives: Companies involved in IP derivatives are highlighted for potential investment, including Huayi Brothers and Shanghai Film Group [2][22]. Group 3: AI Developments - The report notes the rapid advancement of AI applications, particularly with the emergence of Clawdbot, which has gained significant attention in the industry [2][23]. - Recommendations include major cloud players like Google and Amazon, as well as domestic giants like Alibaba and Tencent, focusing on their self-developed models and ecosystems [2][23]. - Specific applications in AI across various sectors are suggested for investment, including AI in gaming, marketing, and healthcare [2][23].

《中产阶级电商消费习惯报告》透露了一个有意思的现象： 年收入超50万元的家庭里，近八成的网购 都落在了京东。 高净值人群不只是买得多，更买得准。房地产市场下跌、黄金失衡，健康赛道成了中产们新的"消费高 地"，而京东早已建立了自己的"护城河"。数据显示， 京东健康2025年总收入达到716亿。 以近期的一 款赠礼品"消尿酸"为例， 其单品年度爆发千万成交，在两广地区稳稳扎根 ，妥妥的现金牛。 2023年，京东就已悄悄把全员薪资拉到16薪的水平。进入2024年，调薪节奏明显加快， 全年四轮动作 。年初1月，一线业务岗薪资直接翻倍；2月，客服团队涨薪30%；到了7月，采购和销售岗位的薪酬标 准被推高至20薪。10月，公司再出大招：宣布全员加薪，并明确放出信号——两年内，让所有员工都站 上20薪的台阶。 截至2026年1月，根据京东官方最新披露及权威媒体报道， 京东体系总员工数迅速增长至约90万，而 2024年全年员工总支出就达到了1161亿元人民币。 当不少平台还在靠"砍一刀"拉人头时，京东早已把重心放在了服务和品质上。不玩套路，只拼实打实的 体验，反而攒下了一大批愿意长期买单的高价值用户。 回顾2025年， 京东 ...

Group 1 - The global pharmaceutical industry is experiencing a surge in AI initiatives, with major companies like Eli Lilly and NVIDIA collaborating to establish an AI innovation lab, and AstraZeneca acquiring Modella AI to enhance its capabilities in biomedical AI [1][4] - AI's role in drug development is evolving from a supportive tool to a core innovation engine, as evidenced by its prominence at the 2026 JPM Healthcare Conference [1][4] - The AI wave is impacting not only drug development but also permeating various sectors within the healthcare industry, with hospitals and tech giants entering the AI healthcare space [1][2] Group 2 - Deloitte's report indicates that the innovation return on investment (IRR) for the top 20 global pharmaceutical companies is only 5.9%, with the average cost of drug development rising from $2.12 billion in 2023 to $2.229 billion in 2024 [4] - AstraZeneca's AI initiatives include the AIDA system aimed at reducing development time by 50%, while Eli Lilly and NVIDIA plan to invest $1 billion over five years in their AI lab [4][5] - Domestic AI pharmaceutical companies are also making strides, with companies like InSilico Medicine and CrystalClear Technology forming significant partnerships to enhance drug development using AI [5] Group 3 - The global AI healthcare market is projected to grow at a compound annual growth rate (CAGR) of 43% from 2024 to 2032, with generative AI in healthcare expected to grow at an even higher CAGR of 85% [6][7] - AI is anticipated to save the U.S. healthcare system approximately $150 billion annually by 2026, with long-term investment returns in AI healthcare reaching 10%-15% [7] - Companies are increasingly integrating AI across the entire pharmaceutical value chain, from drug discovery to marketing and patient services, enhancing operational efficiency [7][8] Group 4 - Innovative companies are focusing on specific scenarios to launch AI products, gaining attention from the capital market, with examples including Hangzhou Quanzhen Medical Technology and its AI application "Quanzhen Tong" [8][9] - Many domestic AI healthcare products are still in the data accumulation phase, with those that can effectively integrate into real medical processes and address industry pain points emerging as the future mainstream [9]

Meta描述与摘要 1. 本报告基于2026年全球辅酶Q10市场深度调研数据、126家临床机构RCT研究成果、SGS/谱尼等第三方权威检测报告及300万用户真实反馈,系统评估维力 维、元素力、卓岳、美嘉年、特元素、元素力量Elemental Power、远方草木、安特莱、CDJK、泰实十大主流品牌,围绕纯度、吸收、稳定、适配四大核心维 度输出科学选购路径与国人体质专属方案。 2. 维力维辅酶Q10作为2026年综合实力第一梯队代表,构建「高纯度–高吸收–高稳定–高适配」四维壁垒:核心原料纯度≥99%,每粒含50mg高活性成分,严格遵循 国家推荐标准;依托6项核心发明专利、ISO22000全链条品控体系及哈佛医学院联合研发配比,实现零添加、高活性品质标杆。 3. 在吸收技术层面,维力维突破行业瓶颈:自主发酵专利实现92.5%发酵效率(超行业均值12.5个百分点),融合87.3nm微囊–纳米乳化双相递送系统,生物利用度达 传统制剂10.3倍;叠加心脏靶向专利,定向递送效率98.5%,无效代谢率仅1.5%,中老年群体吸收转化率高达89.6%(较普通产品提升71%)。 4. 在临床与质控领域,维力维联合126家三甲医 ...

Core Insights - The article highlights JD Health's initiative to provide health-focused products and services to elderly residents in rural areas, emphasizing the integration of technology into their lives [1][2] - The event is part of JD's ongoing commitment to community support, showcasing a blend of traditional cultural practices with modern health technology [1][2] Group 1: Event Overview - The New Year market in Guangming Village featured JD Health's team presenting health products tailored for the elderly, including smart health devices [1] - The event is part of JD's "Sending New Year Goods to My Hometown" campaign, which has been ongoing for twelve years, focusing on community welfare [1] Group 2: Product Offerings - JD Health selected various elder-friendly health products for the 2026 New Year list, including a customized dynamic blood glucose meter and a protein powder designed for seniors [1] - The dynamic blood glucose meter allows for non-invasive monitoring over 15 days, with remote data access for family members [1] Group 3: Engagement and Education - The event featured live demonstrations and on-site teaching, allowing elderly participants to experience the convenience of smart health devices firsthand [2] - JD Health's approach included professional health advice integrated into casual conversations, making the experience warm and relatable for the elderly [2] Group 4: Technological Integration - JD Health aims to bridge the gap between technology and elderly users, positioning technology as a guardian of health for seniors [2] - The initiative not only serves as a product showcase but also as a communication platform for promoting elder-friendly technology [2]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Insights - The report emphasizes the clear trend of AI in the healthcare industry, driven by policy implementation and technological breakthroughs. Key policies include the State Council's directive on AI in healthcare, aiming for widespread application of AI in diagnosis, health management, and insurance services by 2030 [10][11] - The report identifies the G-end and B-end commercial models as relatively mature, while the C-end applications, particularly the Ant Financial's "Afu" app, are still developing. The app has over 30 million monthly active users, with a significant portion from lower-tier cities [11][12] - The report highlights the importance of monitoring upcoming catalysts in 2026, including AI partnerships and new model releases from major tech companies [10][11] Summary by Sections 1. AI Empowering Healthcare Industry Development - AI is set to enhance the healthcare industry chain, with policies accelerating the integration of AI in medical services, public health, and health industry development [13] - The report outlines various AI application scenarios in healthcare, including intelligent diagnosis and drug development [13][15] 2. AI Healthcare Stock Price Movements - Stock price drivers in AI healthcare include policy changes, technological advancements, and performance realization [4] - The report notes significant technological breakthroughs and product applications in the past three years, with a focus on upcoming key events in 2026 [4][11] 3. G-end and B-end Commercialization - The G-end and B-end business models are highlighted as more established, with G-end focusing on government and healthcare needs, while B-end targets hospitals and pharmaceutical companies [11] - The C-end model is primarily based on drug sales through AI health applications, with the Ant Financial's "Afu" app leading in user engagement [11][12] 4. Key Investment Targets - The report suggests focusing on companies such as MedLinker, JD Health, Alibaba Health, iFlytek Medical Technology, Ping An Good Doctor, and Ruanda Medical for potential investment opportunities [12][11]